EULAR 2012 Investor Science Call
Roche conference call for investors and analysts from EULAR 2012
ADACTA, a phase IV study evaluating the reduction in rheumatoid arthritis disease activity during monotherapy treatment with Actemra compared to adalimumab.
The conference call took place on: Friday, 8 June 2012
Investor Updates
- Roche's RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy read more
- Roche conference call for investors and analysts from EULAR 2012 read more